Dr Lawrence Korngut is a neurologist, clinical neurophysiologist and Director of the Calgary Neuromuscular Program and the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He is the National Principal Investigator of the Canadian Neuromuscular Disease Registry that now includes 31 participating clinics and over the past ten years has recruited over 4400 patients.
Dr Korngut is the former Chair of the Canadian Neuromuscular Diseases Network (CAN-NMD), which was funded by the Canadian Institutes of Health Research and Muscular Dystrophy Canada in 2014 and consists of a nationwide collaboration of researchers, clinicians, and allied health professionals aiming to improve the lives those affected by neuromuscular conditions through improving clinical care, research capacity and education. He is the former Chair of the Medical and Scientific Advisory Committee and served on the Board of Directors of Muscular Dystrophy Canada.
Dr Korngut completed his undergraduate degree in Life Sciences at Queen’s University (Kingston, Canada), medical school and neurology residency at Western University (London, Canada), neuromuscular clinical and research fellowship and Masters of Science in Clinical Epidemiology at the University of Calgary, Alberta, Canada. He serves as the Director of Innovation and Commercialization at the Hotchkiss Brain Institute.
Within NMD4C Dr Korngut will bring in his experience of Canadian networking in CAN-NMD and participates in the network’s work in trial capacity building.
Slayter, J, Hodgkinson, V, Lounsberry, J, Brais, B, Chapman, K, Genge, A et al.. A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. J Neuromuscul Dis. 2021. PMID:33867362
Dadar, M, Manera, AL, Zinman, L, Korngut, L, Genge, A, Graham, SJ et al.. Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43. Brain Commun. 2020.2 (2)fcaa061 PMID:33543125
Russell, A, Hahn, C, Chhibber, S, Korngut, L, Fine, NM. Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients. Can J Neurol Sci. 2020. 1-9 PMID:33342448
Chenji, S, Ishaque, A, Mah, D, Fujiwara, E, Beaulieu, C, Seres, P et al.. Neuroanatomical associations of the Edinburgh cognitive and Behavioural ALS screen (ECAS). Brain Imaging Behav. 2020. PMID:33155172
Shefner, JM, Andrews, JA, Genge, A, Jackson, C, Lechtzin, N, Miller, TM et al.. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021.22 (3-4)287-299 PMID:32969758See more on PubMed